# Nano-X Imaging Ltd. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Nano-X Imaging Ltd.). ## Overview Nano-X Imaging Ltd. develops medical imaging systems and related software for radiology and healthcare providers. Its business centers on the Nanox.ARC imaging system, AI-enabled imaging software, and radiology services delivered through a multi-segment structure that also includes healthcare IT capabilities. ## Products & services • Nanox.ARC imaging systems and related capital equipment • Nanox.AI imaging software and clinical workflow tools • Radiology services and network-based scan delivery • Healthcare information technology solutions • Distribution and reseller arrangements for imaging products - **Nanox.ARC imaging systems** (45%) — Capital equipment and deployed imaging systems sold through direct and distribution channels. - **AI and software solutions** (25%) — AI-enabled imaging software, analytics, and workflow tools used by imaging providers. - **Radiology services** (20%) — Scan-related services and network-based imaging delivery offered to healthcare customers. - **Healthcare IT solutions** (10%) — Healthcare information technology products and services added through acquisition. - Nanox.ARC imaging systems and related capital equipment - Nanox.AI imaging software and clinical workflow tools - Radiology services and network-based scan delivery - Healthcare information technology solutions - Distribution and reseller arrangements for imaging products ## Customers Customers include hospitals, orthopedic centers, integrated delivery networks, and other imaging providers that use the company’s systems and software in clinical settings. The company also serves distributors, resellers, and healthcare IT buyers that help broaden deployment across geographies and customer types. Its products are sold into healthcare workflows where buyers seek imaging access, diagnostic capability, and software-driven operational efficiency. - **Hospitals and health systems** (primary) — Buy Nanox.ARC systems and related services to expand imaging access and diagnostic capacity. - **Orthopedic and specialty centers** (primary) — Purchase imaging systems for specialty diagnostic use cases and local scan delivery. - **Integrated delivery networks** (secondary) — Use deployed systems across larger care networks where multi-site imaging access matters. - **Distributors and resellers** (secondary) — Buy or place products to extend commercial reach in the U.S., Latin America, and other markets. - **Healthcare IT buyers** (secondary) — Acquire software and IT solutions for imaging workflow, data management, and clinical operations. - Hospitals and health systems deploying imaging equipment - Orthopedic centers using systems for musculoskeletal imaging - Integrated delivery networks buying multi-site imaging capacity - Distributors and resellers extending market reach - Healthcare IT customers buying workflow and software tools ## Geography The company is headquartered in the United States but operates with a meaningful international footprint, including Israel-linked operations and manufacturing activities in South Korea. Recent disclosures highlight commercial expansion in the U.S. and distribution development in Latin America, with Costa Rica cited as a market entry point. Its operating footprint matters because imaging hardware, software deployment, and supply chain execution are all tied to region-specific regulators, distributors, and manufacturing partners. - Headquartered in the United States - Commercial expansion across the U.S. through distribution partners - Latin America presence supported by Costa Rica distribution agreement - Operations and manufacturing activities linked to South Korea - Israel is a key operating and development center ## Strategy Nanox is focused on broadening commercial deployment of its imaging platform through distribution agreements, clinical pilots, and installed-system placements. It is also building a network-based model around imaging access while expanding the AI and software layer that can be sold alongside hardware and services. The company’s recent emphasis on third-party manufacturing and partner-led distribution shows a strategy built around reach, scalability, and external channel leverage. - **Expand U.S. commercial deployment** (short-term) — The U.S. is the largest addressable market and a key reference market for clinical adoption. - **Scale installed base and network usage** (medium-term) — Deployed systems and network scans create the operating base for recurring customer relationships. - **Grow AI and software commercialization** (medium-term) — Software can extend the platform beyond hardware sales and improve customer stickiness. - **Improve manufacturing and supply chain execution** (short-term) — Third-party manufacturing can reduce operational complexity and support product availability. - Expand U.S. commercialization through distribution partners - Place Nanox.ARC systems in hospitals and specialty centers - Grow Nanox.AI through resellers and pilot programs - Build the Nanox Imaging Network for scan delivery - Use third-party manufacturing to improve supply resilience ## Risks Nanox faces commercialization risk because its business depends on customer adoption of a relatively new imaging platform and on distributor execution in each market. It also carries manufacturing and supply-chain risk, particularly where semiconductor and hardware production depend on external partners. In addition, the company is exposed to impairment risk, regulatory and clinical adoption risk, and the usual execution challenges of a medical technology platform business. - **Commercial adoption risk** [high] — Revenue depends on hospitals and providers choosing a newer imaging platform over established alternatives. - **Supply-chain and manufacturing risk** [high] — Chip production and hardware availability depend on qualified third-party partners and operating discipline. - **Asset impairment risk** [high] — Management disclosed reduced forecasts and impairment indicators in the AI solutions business unit. - **Distribution and channel risk** [medium] — Growth depends on partners that may not generate expected customer placements or reseller traction. - Customer adoption risk for a new imaging platform - Distributor execution risk across U.S. and international markets - Manufacturing and supply-chain dependence on third parties - Impairment risk in software and imaging asset groups - Regulatory and clinical adoption hurdles in healthcare imaging ## Accounting Revenue recognition can vary across equipment, software, services, and distribution contracts, so investors should watch how contracts are classified and when control transfers. The company also has meaningful intangible assets and acquisition-related balances, making impairment testing and valuation assumptions especially important. Lease accounting, contingent earnout liabilities, and deferred revenue can also affect reported operating results and balance sheet comparability. - **Revenue recognition** — Affects quarter-to-quarter comparability and deferred revenue balances - **Intangible asset impairment** — Can materially reduce asset carrying values and increase non-cash charges - **Contingent earnout liability** — Can create volatile non-cash fair value adjustments - **Deferred revenue** — Influences timing of recognized sales and contract liabilities - Revenue timing across hardware, software, services, and distribution - Intangible asset impairment and valuation assumptions - Contingent earnout liability remeasurement - Deferred revenue tied to customer and service contracts - Lease accounting for operating locations and facilities --- *Last updated: 2026-09-28T12:13:23.213136+00:00*